Sippican Capital Advisors Sells 455 Shares of Johnson & Johnson $JNJ

Sippican Capital Advisors lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,410 shares of the company’s stock after selling 455 shares during the quarter. Sippican Capital Advisors’ holdings in Johnson & Johnson were worth $521,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC boosted its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new position in Johnson & Johnson in the first quarter worth $218,000. GAMMA Investing LLC boosted its position in Johnson & Johnson by 48.0% in the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after purchasing an additional 14,118 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Johnson & Johnson by 6.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 1,698,831 shares of the company’s stock worth $281,734,000 after purchasing an additional 107,009 shares during the last quarter. Finally, Hanson & Doremus Investment Management boosted its position in Johnson & Johnson by 9.7% in the first quarter. Hanson & Doremus Investment Management now owns 15,227 shares of the company’s stock worth $2,525,000 after purchasing an additional 1,349 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Sanford C. Bernstein upped their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. HSBC upped their price target on Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. The Goldman Sachs Group upped their price target on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Bank of America upped their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $193.88.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $190.88 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.40. The firm has a market cap of $459.70 billion, a price-to-earnings ratio of 20.41, a PEG ratio of 2.40 and a beta of 0.40. The business’s fifty day moving average is $179.28 and its 200 day moving average is $164.16.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $24.02 billion for the quarter. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.